MW ADVISORY, LLC’s AstraZeneca AZN Stock Holding History

MW ADVISORY, LLC’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$451K	Buy	+2,376	New	+$447K	0.18%	80

Other funds holding AZN

EPGL

Evelyn Partners Group Ltd London $46.9B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

MW ADVISORY, LLC's AZN Position: Q2 2026 in Review

MW ADVISORY, LLC opened a new position in AstraZeneca (AZN) in Q2 2026: 2,376 shares worth $451K. The stake represents 0.18% of the portfolio and ranks #80 among its holdings.

906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

MW ADVISORY, LLC held 2,376 shares of AstraZeneca worth $451K as of Q2 2026.
AstraZeneca was a new MW ADVISORY, LLC position in Q2 2026.
AstraZeneca made up 0.18% of MW ADVISORY, LLC's portfolio in Q2 2026, its #80 holding.
906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on MW ADVISORY, LLC's 13F filing for Q2 2026, filed 7 Aug 2026.